Prostate Cancer | Disease Landscape & Forecast | G7 | 2025

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), dominating current treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., J&J Innovative Medicine’s Akeega, Pfizer’s talazoparib) and radioligand therapies (Novartis’s Pluvicto), and anticipated approvals of emerging therapies (e.g., AstraZeneca’s saruparib and Merck’s opevesostat), will drive robust market growth over the 2024-2034 forecast period.

Questions answered

• What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?
• How will the prostate cancer market evolve over the 10-year forecast period? What are their drivers and constraints?
• What are interviewed experts’ insights on the current treatment options for prostate cancer?· How will the adoption and anticipated label expansions of biomarker-driven therapies, such as PARP inhibitors and PSMA-targeted radionuclide therapies, reshape the prostate cancer treatment landscape?
• What is the clinical and commercial potential of emerging regimens, like opevesostat and saruparib? How are they likely to be positioned in the market?

Geography: United States, EU5, Japan

Primary research: 18 country-specific interviews with thought-leading medical oncologists and urologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Incidence of prostate cancer by country, segmented by risk of biochemical recurrence and TNM staging; market-relevant drug-treatable and drug-treated populations

Forecast: 10-year, annualized, drug-level sales and patient share of key prostate cancer therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.